Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Sublingual minoxidil helped regrow hair in a person with congenital triangular alopecia.

This study reported that platelet-rich plasma injections led to only temporary improvement in vellus hair characteristics in temporal triangular alopecia, suggesting it may not be an effective long-term treatment.

In this study, extracts of Zataria multiflora Boiss. and Matricaria chamomilla, combined with minoxidil, significantly improved hair growth in androgenetic alopecia patients by potentially inhibiting 5α-reductase activity.

The safety of the hair loss drug finasteride is unclear due to inadequate reporting in clinical trials.

Low-level light therapy significantly increased hair density and thickness in people with hair loss, but they didn't notice a difference.

5% minoxidil foam used once daily is as effective as 2% minoxidil solution used twice daily for hair loss in women, but with fewer side effects like itching and dandruff.

This study found that a new topical agent, Scalp medⓇ, significantly improved hair count and thickness in men with androgenetic alopecia after 24 weeks of treatment.

This phase I study found that MK-2206 was well tolerated and demonstrated evidence of AKT signaling blockade in patients with advanced solid tumors, with the maximum-tolerated dose established at 60 mg.

This consensus statement discusses guidelines for screening, diagnosing, and treating the Female Athlete Triad, and introduces a risk stratification system to assist healthcare providers with sports participation decisions.

This study found that neoadjuvant chemotherapy followed by interval debulking surgery led to better quality of life and lower perioperative morbidity compared to primary debulking surgery in advanced epithelial ovarian cancer patients with high tumor load.

This study found that 5% topical minoxidil significantly increased hair regrowth and improved psychosocial perceptions of hair loss in men with androgenetic alopecia compared to 2% topical minoxidil and placebo over 48 weeks.

In this 48-week trial, 5% topical minoxidil was more effective than both 2% minoxidil and placebo in promoting hair growth in women with female pattern hair loss, with notable improvements in nonvellus hair count and hair growth assessments.

In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.

This study found that in women undergoing chemotherapy after breast surgery, topical minoxidil significantly shortened the duration of hair loss compared to a placebo without significant side effects.

This study found that all four treatments—flutamide, finasteride, ketoconazole, and EE-CPA—significantly reduced hirsutism, but EE-CPA and flutamide appeared most effective, with varying effects on androgen levels and side-effect profiles.

This phase II trial found that BI 2536 demonstrated limited antitumor activity across five solid tumor types, with no confirmed objective responses observed.

This study observed that finasteride and spironolactone both led to a similar significant, but limited, improvement in hirsutism despite their differing effects on androgen levels.

In this study, 50 mg/day of DHEA supplementation in postmenopausal women did not significantly improve sexual function compared to a placebo over 26 weeks.

In this study, PRP increased hair density in areas treated for androgenetic alopecia, but there was no significant difference when compared to placebo-treated areas.

This review discusses the potential of adipose-derived stem cells for hair regeneration and suggests that these cells and their conditioned media may offer a promising strategy for treating hair loss.

This study confirmed that 5% topical minoxidil is more effective than 1% in increasing hair density in Japanese men with androgenetic alopecia, with no significant difference in adverse event rates.

This study found that systemic mycophenolate mofetil and topical clobetasol were equally effective at reducing lichen planopilaris activity over six months, but satisfaction differed between the treatments.

This study found that flutamide, finasteride, ketoconazole, and EE-CPA all significantly reduced hirsutism scores, hair diameter, and hair growth rate in women with hirsutism over 12 months.

In this study, heavy nighttime physical exercise delayed the circadian phase of clock gene expression by 2 to 4 hours in a professional fighter, suggesting potential implications for managing circadian disorders.

In this study, a very-low-calorie diet led to greater weight loss and improvements in hyperandrogenaemia and metabolic markers in obese women with polycystic ovary syndrome compared to a moderate energy deficit approach over eight weeks.

This study found that high-dose vitamin A and E supplementation with zinc may improve glycemic control and beta-cell function in patients with type 2 diabetes, compared to no supplements.

This review discusses the pharmacologic effects, safety, and efficacy of dutasteride and finasteride for BPH, finding similar clinical benefits but greater DHT reduction with dutasteride and reports no new trial results.

In this study, women with PCOS who took 12 mg of Astaxanthin daily for 8 weeks showed a reduction in certain inflammatory markers and apoptosis-related genes, suggesting potential benefits for managing PCOS, though effects on symptoms like BMI and hirsutism were not significant.